BRIDGEWATER, N.J., Dec. 1, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that it will participate in the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference in San Francisco. Will Lewis, President of Aegerion, is scheduled to present on Tuesday, December 7, 2010, at 5:30 p.m. EST (2:30 p.m. PST).
A live webcast of the presentation will be available and can be accessed for 90 days following the conference by visiting the " Investors " section of Aegerion's website, .
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in Phase III clinical development. Lomitapide is initially being developed to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia (FC).
CONTACT: Aegerion Pharmaceuticals, Inc. Corporate Will Lewis, President +1 (908) 704-1300 LaVoie Group, Inc. Investors & Media Amanda Murphy +1 (978) 745-4200 x107 amurphy@lavoiegroup.com